A detailed history of Hrt Financial LP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Hrt Financial LP holds 20,044 shares of BCRX stock, worth $152,334. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,044
Holding current value
$152,334
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$6.41 - $8.69 $128,482 - $174,182
20,044 New
20,044 $152,000
Q4 2023

Feb 09, 2024

BUY
$4.98 - $6.77 $396,975 - $539,663
79,714 Added 37.48%
292,412 $1.75 Million
Q3 2023

Nov 13, 2023

BUY
$6.71 - $7.92 $460,547 - $543,597
68,636 Added 47.64%
212,698 $1.51 Million
Q2 2023

Aug 11, 2023

BUY
$6.96 - $8.81 $569,599 - $721,001
81,839 Added 131.53%
144,062 $1.01 Million
Q1 2023

May 12, 2023

BUY
$7.94 - $11.84 $494,050 - $736,720
62,223 New
62,223 $518,000
Q3 2022

Nov 14, 2022

BUY
$10.79 - $14.81 $256,834 - $352,522
23,803 New
23,803 $299,000
Q4 2021

Feb 14, 2022

SELL
$11.18 - $15.46 $1.41 Million - $1.95 Million
-126,125 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $107,640 - $133,698
7,575 Added 6.39%
126,125 $1.81 Million
Q2 2021

Aug 16, 2021

BUY
$9.5 - $17.24 $747,840 - $1.36 Million
78,720 Added 197.64%
118,550 $1.87 Million
Q1 2021

May 17, 2021

SELL
$7.37 - $13.61 $1.93 Million - $3.56 Million
-261,852 Reduced 86.8%
39,830 $405,000
Q4 2020

Feb 16, 2021

BUY
$3.37 - $8.61 $1.02 Million - $2.6 Million
301,682 New
301,682 $2.25 Million
Q4 2019

Feb 14, 2020

SELL
$1.59 - $3.45 $123,104 - $267,112
-77,424 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$2.5 - $3.73 $193,560 - $288,791
77,424 New
77,424 $221,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.